Phenolic compounds (PCs) are plant-derived secondary metabolites recognized for their diverse biological activities, including antioxidant, anti-inflammatory, and anti-diabetic properties. While conventional oral hypoglycemic agents like metformin and glimepiride are widely used to manage blood glucose, they are often associated with adverse effects such as gastrointestinal distress, allergic reactions, and liver inflammation. This study utilized molecular docking to evaluate the anti-diabetic potential of 29 plant-based phenolic compounds compared to standard marketed drugs. The results demonstrate that all 29 natural compounds exhibited superior docking scores and glide energy relative to the reference standards, suggesting their potential as safer and more effective alternatives for blood glucose regulation.
Patil et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: